BioSpace News Archive

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share.

Onconova Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $1.00 per share.

Core One Labs Inc. is pleased with the tremendous turnout on the International Investors’ Call held earlier.

Zymo Research announced their COVID-19 Variant Sequencing Service. This new global service expands Zymo Research’s end-to-end SARS-CoV-2 solutions that include sample collection, RNA extraction, and SARS-CoV-2 detection.

Skin cooling systems work by chilling the skin layer, thereby minimizing the pain at the injury or pain point.

Fact.MR, a global research & consulting firm, in their updated edition of the report, projected that the canine influenza treatment market is poised to witness a robust growth in 2021 & beyond.

Fact.MR, a global research & consulting firm, in their latest edition of the report, projected that the osteoporosis testing market is likely to foresee a steady growth pace in 2021 & beyond.

Immunoprecipitation is a process of separating protein from biological samples. Here, the protein is isolated using a specific antigen.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”), a leading provider of high-quality, long-read sequencing platforms, today announced that SB Management, a subsidiary of Softbank Group Corp., will make an investment of $900 million in convertible senior notes to support the Company’s future growth initiatives.

Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, in its pursuit to meet the urgent need for new therapeutic options for patients with pancreatic cancer, has been evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel